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Prions consist of pathological assemblies of normal cellular prion protein and cause
infectious neurodegenerative diseases, a phenomenon mirrored in many other prion-like
neurodegenerative diseases. However, despite their key importance in disease, the indi-
vidual processes governing this formation of pathogenic aggregates, as well as their rates,
have remained challenging to elucidate in vivo. Here we bring together a mathemati-
cal framework with kinetics of the accumulation of prions in mice and microfluidic mea-
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surements of aggregate size to dissect the overall aggregation reaction into its constituent
processes and quantify the reaction rates in mice. Taken together, the data show that
multiplication of prions in vivo is slower than in in vitro experiments, but efficient when
compared to other amyloid systems, and displays scaling behaviour characteristic of ag-
gregate fragmentation. These results provide a framework for the determination of the
mechanisms of disease-associated aggregation processes within living organisms.
Prions contain no conventional genetic information, yet, prions are infectious in a manner rem-
iniscent of viruses (1, 2). To cause this behaviour, a small number of prions introduced upon
infection have to be able to induce the formation of more prions, and this replication of infec-
tious entities is thus the central process in prion diseases. This ability to replicate allows the
disease to be initiated by a small number of particles, enabling prions to propagate from host
to host and cause a rapidly progressive disorder. Although effects detrimental to the organism
occur late in the development of the disease, and the detailed mechanism of toxicity is not yet
fully established, the infection by and replication of prions is the crucial prerequisite for disease
and thus understanding prion replication is central to understanding prion diseases (3–5). Prion
disease is the archetypal aggregation-associated disease and in other neurodegenerative diseases
the formed aggregates of proteins such as tau and α-synuclein are often termed prion-like for
similarities in their mechanism of propagation (6–8). Given this analogy with prion disease, the
insights gained and framework developed here is likely to be of relevance to a wide range of
disorders.
To avoid any confusion arising from the use of terminology from both the fields of prion
diseases and of protein aggregation, we define here explicitly the terms used as: Infectious
units are species capable of inducing the disease when introduced into a host (their relation
to the species causing pathology is not required for this definition), infectivity is a measure of
their concentration. In practice, infectivity is usually determined in dilution experiments, for
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example within mice (9) or in cell culture, through the Standard Scrapie Cell Assay (SSCA)
(10). Aggregates are structures of several proteins in the PrPSc state, the process that increases
the size of a given aggregate is referred to as growth. Multiplication is the specific process that
increases the number of aggregates, such as fragmentation of an existing aggregate. Replication
is the overall process that converts molecules in the PrPC state to molecules in the PrPSc state.
Thus the rates of growth, multiplication and replication denote the rate of increase of size of a
given aggregate, the rate at which a given aggregate produces new ones and the overall rate at
which PrPC is converted to PrPSc.
It has been established that the conversion of monomeric cellular PrPC (here also referred
to simply as monomer) to PrPSc is at the core of the ability of prions to replicate (11). How-
ever, the molecular mechanisms, including the individual processes and their rates, by which
existing infectious units can interact with PrPC and produce new infectious units have not been
established in vivo. Numerous models have been proposed, including a direct conversion mech-
anism, whereby each protein in the PrPSc state can catalyse the conversion of soluble PrPC
molecules into PrPSc via a hetero-dimer (12) and a fragmentation mechanism, whereby a large
prion may break apart into two new prions (13) but it has remained challenging to verify either
of these models in vivo. The majority of mechanistic studies have therefore to date focused
instead on the kinetics of the aggregation of purified recombinant PrP in vitro (11, 14, 15) and
found the half time of aggregation to scale inversely with the square root of monomer concen-
tration, which, as we and others have shown in the past (16), is consistent with a multiplication
of aggregates by fragmentation. The relevance of these findings for the proliferation of prions in
vivo remains, however, unclear, in particular as samples of aggregated, recombinant PrPSc pro-
duced in vitro display considerably lower infectivity when injected into mice than the types of
aggregates found in the brains of diseased organisms (17), suggesting a significant difference in
structure, composition or mechanism. Overall, therefore, the mechanisms of prion replication
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on a molecular level remain to be established in vivo.
In order to address this challenge, we present a general framework for obtaining robust,
representative parameters from in vivo data and relating them to fundamental mechanisms of
multiplication and growth of protein aggregates. This approach is general enough to yield a
continuous spectrum of behaviour, linking the previously proposed mechanisms (13, 18–24).
Here, we show its power in analysing mechanisms in living systems by determining the rates
for prion growth and multiplication in vivo.
Results
Mechanistic analysis of prion multiplication.
Chemical kinetics is the gold standard tool for discovering and verifying reaction mechanisms
in molecular sciences, and this framework has recently been extended to protein aggregation
where it fundamentally aids the mechanistic characterisation of complex reaction networks. In
the present work, we apply this approach to aggregation taking place in a living system (Fig. 1a).
To obtain in vivo data amenable to mechanistic analysis within the framework of chemical
kinetics, we studied the kinetics of PrPSc formation in a total of 78 mice from four different lines;
they include wild type (WT, also referred to as Prnp+/+) mice and genetically modified mice
that express approximately half (heterozygous WTxPrnp0/0, also referred to as Prnp0/+), twice
(heterozygous tga20xPrnp0/0, also referred to as tga20Prnp0/+) and three to four times (tga20,
also referred to as tga20Prnp+/+) the level of PrPC found in the WT mice. Crucially, studying
the aggregation at different concentrations of PrPC allows the determination of the dependence
of the aggregation rate on the PrPC concentration, which in turn can be linked to the nature of the
replication mechanism. To initiate aggregation, the mice were inoculated intra-cerebrally with a
well-characterized prion inoculum (RML5). We collected brain samples from each mouse line
at multiple time points after inoculation until the onset of terminal disease, and measured levels
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of proteinase-K (PK) resistant and total PrPSc (i.e. the sum of PK sensitive and PK resistant) as
well as the levels of PrPC in the brains of inoculated mice. Additionally, we performed separate
experiments to determine the time course of infectivity, using a standard scrapie cell assay, for
a separate cohort of wild type mice (details see methods). To further increase robustness of
our analysis, we combine our data with similar datasets from previous works. Finally, we used
measurements of the molecular diffusivity of the aggregates to determined the average size of
prions directly in brain homogenate.
Infectivity and PrPSc increase exponentially.
An initially exponential increase in the number of aggregates is the hallmark of all aggregation
mechanisms that include a multiplication and a growth process and emerges as a natural result
of the auto-catalytic nature of self-replication, as we outline later and discuss in more detail in
Supplementary Note 1 and Meisl et al. (25). Indeed, the results from our kinetic assay were
consistent with an exponential increase in PrPSc for the majority of the time-course, although
PrPSc amounts plateau late in the disease, as observed in previous studies (26, 27). To further
verify the exponential increase, given that the initial measurements lie below the sensitivity of
the ELISA, we also measured infectivity by SSCA as a function of time in wild type mice of
a separate cohort to that used for the PrPSc measurements (28). The infectivity is found it to
increase exponentially, by several orders of magnitude, consistent with previously published
data by Sandberg et al. (Fig. 1b) (27). Our interpretation of their data differ slightly from those
presented by Sandberg et al. as we find that both the PrPSc concentrations and the infectivity are
consistent with an initially exponential increase and there is no evidence of one lagging behind
the other (see Extended Data Fig. S1).
No PrPSc was observed in age-matched uninfected controls, indicating that exposure to the
RML isolate was essential for inducing PrPSc formation. The average levels of PrPC were found
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to be slightly lower at the terminal disease stage with the most pronounced relative decrease (by
35%) observed for WT (Prnp+/+) mice (Fig.2a). This finding is also in agreement with the



































Figure 1: Principle of mechanistic analysis and increase of infectivity over time. (a) Mice of
four different lines are inoculated with RML prions. At several time-points throughout disease,
from inoculation up to 450 days post inoculation (dpi), the levels of PrPSc and PrPC in mouse
brains, as well as the infectivity of brain homogenate, is determined. The scaling of the rate
of accumulation with PrPC amount serves as a guide to the mechanisms of multiplication. (b)
Infectivity increases exponentially over the majority of the time-course, except the first few
weeks after inoculation and close to terminal disease. The solid lines are straight line fits in
logarithmic space to the filled circles, and show that the rate of increase is faster in mice with
a higher PrPC, the implications of which are discussed in the following sections. Open circles
are data excluded from this fit. Circular points are data from Sandberg et al. (27), diamonds
are data measured by SSCA by us in a cohort of wild type mice separate to that for the PrPSc
measurements (28).
The reduction in PrPC concentration correlates with the appearance of pathological symp-
toms and may be the effect of higher order feedback processes, such as the organism’s response
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to the accumulation of aggregates (26). In the context of an analysis of the kinetics of aggregate
accumulation, the data provide the most robust constraint on the mechanistic details if the direct
effect of the variation in a single parameter (in this case the PrPC concentration) can be mea-
sured. Given the complexity of any aggregate-induced response by the organism and the lack of
knowledge of the exact nature and extent of the effects that a high concentration of aggregates
has on the biochemical processes taking place in the organism, a kinetic analysis is thus most
readily interpreted prior to the build-up of high levels of PrPSc and the appearance of pathology.
We have therefore focused our analysis on the exponential stages of the PrPSc accumulation,
before its concentration plateaus and pathological symptoms of the mice become apparent. In-
fectivity increases by several orders of magnitude during this time period, making it the most
important stage of the disease process to study in the context of prion replication. In practice, to
show the robustness of our findings, we have employed 3 different methods to extract the rates
of replication from these data: (1) a model free approach in which we determine the times at
which a threshold concentration of PrPSc is exceeded for each mouse line, (2) fits of a simple
exponential to the pre-plateau phase, and (3) fits of a sigmoidal function that extends the initial
exponential behaviour to produce a plateau at late times. The results of the last, most sophisti-
cated method are shown here (Fig. 2). The other methods yield essentially unchanged results,
which are shown in Extended Data Fig. S2 and Supplementary Note 2.










where κ is the exponential growth rate, P0 the initial PrPSc concentration and Pmax the PrPSc
concentration at the plateau. This function approaches an exponential growth curve, P0eκt, at



































































































Figure 2: PrPC and PrPSc concentrations over time for different mouse lines. (a) PrPC
concentrations just after inoculation and shortly before terminal disease, for the each of the
four different mouse lines. The concentrations are normalised to the PrPC concentration in
an uninfected wild type mouse. (b-e) PK resistant PrPSc concentration as a function of time,
for each mouse line (the analogous plot for total PrPSc concentration is given in the Extended
Data Fig. S2). The filled circles are data-points in the pre-plateau region, the empty circles
data-points in the plateau region. The solid lines are fits of equation (1) to all data-points. At
each time-point samples from one or more mice were analysed, and 3-4 technical repeats of the
ELISA assay of the same sample were performed (all technical repeats are shown). In total 78
mice were used (for detailed mouse numbers in each line see Extended Data S3). Dotted lines
denote the approximate onset of symptoms (grey regions its standard deviation over remaining
mice). Note the different time axis in b; the other plots, c-e, share the same time axis.
logistic differential equation, the simplest description of auto-catalytic growth with a carrying
capacity. Further details on its importance in describing aggregation reactions can be found in
Meisl et al. (25). Setting P0 and allowing κ and Pmax to vary reproduces the data well as shown
in Fig. 2 (in Supplementary Note 2 we rationalise the choice of P0 and show that the results
are not sensitive to its specific value). The time to double the number of PrPSc aggregates in
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the exponential phase, t2 = ln(2)/κ, is approximately 4 days in the mice with the highest PrPC
concentration (tga20) and 17 days in the mice with the lowest PrPC concentration (Prnp0/+).
Exponential rate depends on PrPC concentration.
A key characteristic of each mechanism of protein aggregation is the dependence of κ on the







The fact that only the relative variation in the exponential rates and monomer concentrations
is required to determine this scaling gives it the necessary robustness to apply to in vivo ex-
periments. Indeed, decades of work on the kinetic analysis of protein aggregation (16, 29, 30)
have shown that the two key characteristics of experimental data rich in mechanistic informa-
tion are the nature of the time dependence (exponential or polynomial) and the concentration
dependence given by γ. The level of infectivity of the inoculum or the absolute quantification
of PrPSc do not affect these quantities, making this approach uniquely suitable as a measure of
the mechanism of aggregation in complex systems.
A graph of κ versus the initial PrPC concentration on a double logarithmic plot allows the
scaling exponent to be visualised (Eq. 2), see Fig. 3. Through this analysis of the rates of
accumulation of PK resistant and total PrPSc for the four mouse lines we find that the rates
scale approximately with the square root of the PrPC concentration, i.e. γ ≈ 1/2. As outlined
above, we verified that our findings are not dependent on the specifics of the data analysis by
extensively investigating the effect of changes in the fitting approaches (see Supplementary
Note 2).
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Figure 3: Scaling exponents of the rate of infectivity and of PrPSc increase. Double loga-
rithmic plots of the rate of accumulation, κ, of infectivity, PK resistant PrPSc all PrPSc. Data
included is from this work, Mays et al. (26) and Sandberg 2014 et al. (27). See Figs. 1b and 2,
as well as Extended Data Fig. S2, S4 and S5 for primary data fits and Supplementary Note 3 for
monomer concentrations and analysis details.
Rates and PrPC dependence are consistent across datasets.
Similar sets of data to those recorded here have been reported independently by Mays et al. (26)
and by Sandberg et al. (27), for three mouse lines in each case. We analysed these data in the
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same manner as the data reported in the present study (see Supplementary Note 3 and Extended
Data Figs. S4 and S5). Three quantities were measured in these studies: the concentration of
PK resistant PrPSc, the concentration of total PrPSc (PK resistant and other species) and the
infectivity. These studies all display an exponential increase in the measured quantity and de-
termining the exponential rates to calculate the scaling for each of the quantities yields very
similar results: The rate, κ, scales approximately as the square root of the PrPC concentration.
Remarkably, this is true for both the PrPSc concentration and the infectivity, although on aver-
age the rates of accumulation of infectivity are slightly higher than those of the accumulation
of PrPSc and the scaling is slightly lower. These differences may be a result of the differing
sensitivities to small prion concentrations of the assays used to measure PrPSc and infectivity.
The doubling times for PK resistant PrPSc obtained in these other datasets are approximately
3 weeks and 1 week for the Prnp0/+ and tga20, respectively, comparable to our data. We
combine all data in Fig. 3 to obtain overall scaling exponents for the total and PK resistant PrPSc
concentrations, as well as the infectivity, which are all approximately 1/2. Values of scaling
exponents and errors for the different methods are summarised in Extended Data Fig. S6.
Scaling exponent informs on replication mechanism.
We now set out to link the experimental observations of the scaling behaviour to the underly-
ing mechanism through a general framework for describing replication of aggregates in vivo.
The general model is obtained by considering the fundamental classes of different processes
that form the reaction network describing the conversion of monomeric proteins to aggregates.
Two distinct types of processes are required to achieve replication of aggregated structures: (1)
growth processes, which are responsible for the conversion of soluble PrPC into its aggregated
form through addition to existing aggregates and (2) multiplication processes, which increase
the number of aggregates. New aggregates in turn are able to grow through addition of solu-
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ble protein again, closing the positive feedback loop between growth and multiplication that is
responsible for the overall exponential increase in aggregate mass (Fig. 4a). It is worth noting
that the hetero-dimer mechanism whereby each molecule in the PrPSc state can convert more
PrPC (2), here referred to as direct monomer conversion, does not involve aggregation and hence
does not distinguish between growth and multiplication processes. However, it can be obtained
as a mathematical limit of the more general model used here and its predictions are shown to be
inconsistent with the data (Fig. 4b).
Growth processes reflect the addition of soluble protein to existing PrPSc aggregates so
are easily described by one general mechanism. However, several different processes may be
responsible for the formation of new aggregates. Under the conditions studied, the de-novo
formation of aggregates from soluble PrPC alone, primary nucleation, was found to be negli-
gible, as no PrPSc accumulation was observed in mice inoculated with prion-free samples (this
extremely slow rate of formation of aggregates directly from PrPC also explains the rarity of
spontaneous prion disease). Thus, any production of new aggregates requires the presence of
existing aggregates and is therefore a multiplication process. We can distinguish between two
fundamental cases: the formation of new aggregates can depend on the concentration of aggre-
gates alone, for example through the fragmentation of existing aggregates, or it can depend on
both the concentration of existing aggregates and the concentration of monomers, for example
in the case where the accessible surface of aggregates acts as a catalyst for the formation of new
aggregates from soluble monomers in a secondary nucleation process (31–34). As the multi-
plication step is responsible for producing new aggregates, it also has to maintain the specific
strain conformation. Differences of the kinetics between strains would, in this framework, be
encapsulated in differing rates of growth and multiplication (35, 36). Finally, we also consider
processes that result in the removal of aggregated species from the system (37,38), for example
autophagy or engulfment by microglia, or processes that prevent them from participating in the
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aggregation reaction, e.g. by incorporation into plaques, to complete the in vivo model. The
detailed assumptions and limitations of this models are discussed in Supplementary Note 1. A
more in depth treatment of the different classes of processes, explicitly considering variations
of their rates with aggregate size, are considered in Meisl et al. (25). Briefly, the population
of aggregates will generally consist of a range of species of different sizes, so to develop a
general description one has to consider how the rate of both growth and multiplication depend
on the size of the aggregate. This can be achieved by defining one continuous parameter each
for growth and multiplication, which yields a continuous spectrum of behaviour that connects
the limiting physical cases of self-replication and also applies to aggregates that are not linear
in geometry. In essence, all mechanisms that include a multiplication step predict an exponen-




≈ eκt where κ is the replication rate. However, the
dependence of this rate on the PrPC concentration can differ and is determined by the reaction
orders with respect to PrPC of both the growth process and the multiplication process. More
specifically, the replication rate is the geometric mean of the growth and the multiplication rates
κ =
√
kmultkgrowth. This conclusion does not require the precise molecular mechanisms of
growth and multiplication to be specified, but applies to all mechanisms that fall into the re-
spective classes. In Fig. 4b the scaling and the functional form of the increase of PrPSc with
time for a selection of common models are compared.
Using the data from the four independent experimental studies, we determined that the in-
crease in PrPSc concentration was exponential and that the scaling exponent was approximately
0.5 (see Fig. 3). Based on these observations several general classes of mechanisms can be
discarded as inconsistent with the experimental data. The exponential increase excludes mech-
anisms that (i) lack multiplication and only involve the growth of inoculated (Fig. 4b II) or (ii)
spontaneously formed aggregates (Fig. 4b III). Such behaviour is observed for example in the
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Figure 4: Reaction network and consistent mechanisms. (a) Monomeric PrPC is represented
by blue spheres and PrPSc aggregates are represented by blue bars. Aggregates can grow by
incorporating more PrPC, and can multiply for example by fragmentation. Growth and multi-
plication couple together in an auto-catalytic manner, the whole cycle is referred to as replica-
tion. Finally, the loss of aggregates by degradation and sequestration into plaques both have
the effect of preventing the removed aggregates from further participating in the aggregation
reaction (b) The scaling exponent, γ, is plotted against the functional form of the increase of
aggregate mass with time, from linear to exponential. For the formation of linear aggregates
without multiplication, the mass increase is linear in the absence of any spontaneous aggregate
formation from monomer alone (II), or low-order polynomial if spontaneous formation of ag-
gregates occurs (III). If aggregates are able to multiply, the mass increase is exponential (I, IV,
V). Fragmentation of aggregates results in a scaling of approximately 0.5 (I), direct monomer
conversion leads to a scaling of 1 (IV), and secondary nucleation gives a scaling 1 or above (V).
low value of the scaling exponent excludes the possibility of (iii) direct monomer conversion
whereby each protein in the PrPSc state may convert more PrPC, also referred to as the hetero-
dimer mechanism, which predicts a scaling of 1 (Fig. 4b IV), (iv) an aggregation mechanism
that proceeds independently of the monomer concentration, which predicts a scaling of 0, (v)
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a mechanism of growth where oligomeric PrPC species, present at low concentrations and in
equilibrium with monomer, are added to growing aggregates, which predicts a scaling of > 1
(Fig. 4b V, scheme not shown) and (vi) a monomer concentration-dependent secondary nu-
cleation process as is observed in vitro in the aggregation of the Aβ peptides associated with
Alzheimer’s disease (40), which also predicts a scaling of 1 or above (Fig. 4b V), depending
on the number of monomeric species that take part in the nucleation reaction and the degree of
saturation (41). Our findings are however in agreement with PrPSc forming linear aggregates
that multiply via fragmentation, γ = 0.5 (Fig. 4b I). They are also consistent with PrPSc forming
higher dimensional aggregates, such as bundles of aggregates that thicken as they grow, that are
less likely to fragment the larger they become (25). It is interesting to compare this result with
data obtained from in vitro studies (16,42) which are indicative of fragmentation being the dom-
inant mode of multiplication in the formation of linear fibrils of PrPSc. Therefore, although the
formed structures and the rates of replication differ significantly, remarkably, the mechanism of
replication in vivo is consistent with the mechanism in vitro.
Prion size in brain homogenate by microfluidic sizing.
A further experimentally accessible quantity, which allows deconvolution of the growth and
multiplication rates from the overall effective rate of replication of PrPSc, is the average size
of the aggregates formed. We used microfluidic diffusional sizing to determine the size of PK
resistant PrPSc aggregates in the brain homogenate of tga20 mice. A schematic of the platform
is shown in Fig. 5. The technique is based on the fact that no turbulent mixing takes place under
the conditions of laminar flow in the microfluidic device, and thus the movement of particles
lateral to the flow direction is governed purely by diffusion and hence by their size. Having
allowed the sample time diffuse, the concentrations are measured by antibody FRET using a
POM antibody (43). Particle-based simulations of the diffusion of different sized species in the
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device (see Extended Data Fig. S7) allow us to relate the measured amounts of signal in each
channel to the diffusion coefficient and thus the size of the detected particle (44). We found that
the diffusion coefficient of PK resistant PrPSc aggregates from the brains of prion-infected tga20
mice at terminal disease was over one order of magnitude larger than PrPC measured by the
same method. To obtain the physical dimensions of the measured species, assumptions about
their size have to be made, which is discussed in more detail below. However, the hydrodynamic
radius related to a given diffusion coefficient is defined as the radius of a spherical particle
that would diffuse at the same rate and can be calculated to assign a more easily interpretable
quantity. It should not be confused with an actual size, if the particles are non-spherical.
Comparison with other disease-associated proteins in vitro.
To further probe the origin of the differences and similarities, and compare the observed data in
mice to the aggregation of other disease-associated proteins in vitro, we set out to obtain values
for the rates of the key processes of growth and multiplication. Growth and multiplication
are connected in a positive feedback loop, Fig. 4a, and thus both contribute to overall prion
replication, which is reflected in the fact that their rates only occur as a product in the rate of
replication, κ =
√
kmultkgrowth. In order to dissect the contribution from the two processes, we
require an additional measurement of an orthogonal property, such as the average number of
PrP subunits in an aggregate. Such a measurement of the average aggregate size under in vivo
conditions represents a major challenge. However, microfluidic diffusional sizing coupled to
immunochemcial detection allows the determination of the size of PK resistant PrPSc aggregates
directly in brain homogenate from mice as detailed above (see Fig. 5). Given the measured
hydrodynamic radius of 87 ± 14 nm and accounting for the range of possible shapes of the
aggregates and the possible presence of molecules other than PrPSc in the aggregate, we obtain
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Figure 5: (a) Layout of the microfluidic device used to size prions in brain homogenate. The
highlighted regions are shown schematically in c. (b) Measured hydrodynamic radii of recom-
binant PrP (”recPrPC”, 2.9 ± 0.3 nm), brain homogenate from uninfected tga20 mice (”unin-
fec”, 3.5± 0.5 nm) and brain homogenate from tga20 mice 60 days post inoculation (”60 dpi”,
87 ± 14 nm). Errors are the standard deviation from 3 technical repeats. Note that for prions,
which are unlikely to be spherical, the hydrodynamic radius is likely an underestimation of their
actual size. Conversion of hydrodynamic radii to number PrP subunits is discussed below. (c)
Schematic showing how sample is injected along with buffer into the left side of the device. Par-
ticles diffuse laterally into the buffer stream, smaller particles diffuse further than larger ones.
The microfluidic channel is eventually split into 2 parts, a diffused and an non-diffused fraction.
The concentration of PrPSc in each fraction is then determined using an antibody FRET assay.
(details see Supplementary Note 4). A number of previous studies have investigated the size of
prions by a variety of methods, from electron microscopy imaging of brain homogenate with
various levels of purification (45, 46) to live cell imaging (47). While they suffer form different
individual drawbacks, they generally find species hundreds of nm in length, with relatively
low aspect ratios, consistent with aggregates composed of several hundreds or thousands of
PrP molecules. A study by Silveira et al. (48) that measured the infectivity as a function of
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size, found that particles consisting only of tens of PrP molecules may already be infectious.
However, even given the harsh treatment of their brain samples by sonication, the majority
of species displayed a hydrodynamic radius between 30 and 60 nm. Our results are therefore
consistent with previous measurements and, as the method we present here is one of the mildest,
are likely to be a good representation of the in vivo prion size.
The average number of subunits per aggregate, µ, is related to the rates of multiplication,
kmult, and growth, kgrowth, by kmult = κ/µ. This decomposition into growth and multiplication
rates is valid for any general growth-multiplication type mechanism, as we outline in Supple-
mentary Note 1 and Meisl et al. (25). For reference, we estimate the rate of multiplication in
the brain of tga20 mice for an intermediate average prion size of 3000 monomers per aggregate
to be 5·10−10 s−1 and the rate of growth to be 5·10−3 s−1, from the average of the rates from
all tga20 datasets. To compare these results to the aggregation of other proteins which has been
measured in vitro, we use previously published values for the rate constants and extrapolate
these to obtain the rates of growth, multiplication and replication at a protein concentration of
135 nM (see Supplementary Note 5), which corresponds to the concentration measured in tga20
mice (26), see Fig. 6. There are clear differences between prion replication in mice and the ag-
gregation of purified PrP in vitro. Most notably, the multiplication rate of prions is orders of
magnitude lower than that of purified PrP. These differences in rates quantify the effect of vari-
ous cellular mechanisms, such as chaperones, whose function is to prevent protein aggregation.
In light of this significant decrease of PrP replication in vivo compared to in vitro, it is quite
remarkable that the rate of replication of prions is still significantly higher than the in vitro rates
of both α-synuclein and tau, proteins whose aggregation plays a central role in Parkinson’s and
Alzheimer’s diseases. The high rate associated with prion replication may lie at the core of the
reason why prion diseases are generally significantly more infectious and progress more rapidly
than these other aggregation-related disorders.
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Figure 6: Individual rates in vivo and in vitro. (a) Rates of growth, multiplication and overall
replication for prions in tga20 mice and a range of other in vitro systems. (b) The growth
rate is plotted against the multiplication rate, lines of constant replication rate are shown as
diagonals. For prions in vivo, the rates obtained assuming prions are elongated structures and
consist between 3000 and 30000 PrP monomers are shown in dark blue, the bounds obtained
without these assumptions are shown in light blue. The rate constants and error bars were
obtained: for PrP and α-synuclein from Sang et al. (42), for tau from Kundel et al. (49), and for
Aβ42 from Meisl et al. (50). The growth and replication rates for the in vitro systems were then
calculated at a monomer concentration of 135 nM, which is the concentration of PrPC in tga20
mice. The error bars for the replication rate of prions are the ranges of rates obtained from the
different analysis methods and different datasets, the error bars for multiplication and growth
are derived from upper and lower bounds on the average aggregate size (see Supplementary
Notes 4 and 5).
Discussion
We have established a general framework for describing aggregation in vivo by using a robust
measure, the scaling exponent. The rates and scaling exponents obtained in this manner can
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be linked to the underlying molecular processes, thus giving insights into the mechanisms of
self-replication. Rates of the processes in this mechanism can be estimated and our results
reveal that the rate of multiplication of prions in vivo is slower than that of aggregates of pure
PrPSc in vitro, but faster than that of α-synuclein and tau in vitro. We designed the application
of this method for the case of mammalian prions, but the approach presented here is general
and we envisage that it will be widely applicable in identifying the mechanism and rates of
self-replication for a range of other aggregating systems in vivo.
References
1. A. Aguzzi, M. Polymenidou, Cell 116, 313 (2004).
2. S. Prusiner, Science 216, 136 (1982).
3. M. K. Sandberg, H. Al-Doujaily, B. Sharps, A. R. Clarke, J. Collinge, Nature 470, 540
(2011).
4. M. Eigen, Biophys Chem 63, A1 (1996).
5. F. Cohen, et al., Science 264, 530 (1994).
6. A. Mudher, et al., Acta Neuropathologica Communications 5, 99 (2017).
7. M. Goedert, F. Clavaguera, M. Tolnay, Trends in Neurosciences 33, 317 (2010).
8. G. Meisl, T. P. Knowles, D. Klenerman, Current Opinion in Neurobiology 61, 58 (2020).
Neurobiology of Disease.
9. S. B. Prusiner, et al., Annals of Neurology 11, 353 (1982).
10. P.-C. Klohn, L. Stoltze, E. Flechsig, M. Enari, C. Weissmann, Proceedings of the National
Academy of Sciences 100, 11666 (2003).
20
11. B. Caughey, D. A. Kocisko, G. J. Raymond, P. T. Lansbury, Chemistry & Biology 2, 807
(1995).
12. S. B. Prusiner, Science 252, 1515 (1991).
13. J. H. Come, P. E. Fraser, P. T. Lansbury, Proc Natl Acad Sci U S A 90, 5959 (1993).
14. K.-W. Leffers, et al., Biological Chemistry 386, 569 (2005).
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Methods
Mice used. For PrPSc measurements: WT (C57BL/6), WT x Prnp0/0, tga20 and tga20 x
Prnp0/0 transgenic mice. Both male and female mice were utilized in this study. The mice were
inoculated at approximately 2 months of age (62 days ± 3 days). For SSCA measurements
and size determination: six-week old C57BL/6J male mice purchased from Charles River (Ger-
many) were inoculated. Mice were maintained on a 12 h:12 h light/dark cycle at an ambient
temperature (21 – 23oC) and 50-60% humidity.
Inoculation of mice for PrPSc and PrPC measurements WT (C57BL/6), WT x Prnp0/0,
tga20 or tga20 x Prnp0/0 transgenic mice (groups of n=10-12 mice) of either sex were intracere-
brally inoculated into the left parietal cortex with 30 µl of 0.01% brain homogenate containing
RML5 (passage 5 of Rocky Mountain Laboratory strain mouse scrapie prions). The titer of the
RML5 inoculum was 8.9 log(LD50) g−1 of brain tissue. tga20 and Prnp0/0 mice have been pre-
viously described (51, 52), and were maintained under specific pathogen-free conditions. Mice
were monitored three times weekly, and prion disease was diagnosed according to clinical cri-
teria including ataxia, kyphosis, stiff tail, hind leg clasp, and hind leg paresis. The mice were
sacrificed at time-points throughout the disease incubation period or at the onset of terminal
disease when showing signs including weight loss, tremors, slow movements, and kyphosis.
Inoculation of mice for infectivity measurements C57BL/6J male mice were purchased
from Charles River (Germany) and allowed at least one week of habituation before inocu-
lations. Experimental manipulations were performed in compliance with the Swiss Animal
Protection Law, and approved by the Veterinary office of the Canton Zurich (animal permits
41/2012, 90/2013, ZH040-15). Six-week old C57BL/6J male mice were injected under isoflu-
rane anesthesia in the right hemisphere with 30 µl of RML6 (passage 6 of Rocky Mountain
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Laboratory strain mouse-adapted scrapie prions, available upon request) at a 10−2 dilution of a
10% homogenate (10% w/v in 0.32M Sucrose, 109.02 LD50 units per mL) (53).
At selected time points after prion inoculation, mice were deeply anesthetized and transcar-
dially perfused with cold PBS before brain collection. Animal experiments were performed in
compliance with the Swiss Animal Protection Law, under the approval of the Veterinary office
of the Canton Zurich (animal permits 41/2012, 90/2013, ZH040-15). Intracerebral injections
were performed under isoflurane anesthesia. All efforts were made to prevent or minimize
animal discomfort and suffering.
Sample preparation for PrPC measurements 10% brain homogenates from RML-infected
mice shortly after inoculation and at the terminal stage were measured by the BCA assay.
200 µg of each brain sample was diluted to 60 µl total volume using phosphate buffered saline
(PBS). Samples were digested using BenzonaseTM (Millipore) with gentle shaking for 20 min
at 37oC, then mixed with 20 µl 4% sarkosyl with shaking for 20 min at 37oC. Samples were then
centrifuged at 16,000 x g for 30 min at 4oC. The supernatants were carefully collected and stored
at -80oC. 50 µl of each sample was injected onto a Fast Performance Liquid Chromatography
(FPLC) column (Superose 6, 3.2/30) using running buffer (50 mM NH4OAc, 0.1% sarkosyl,
pH 8.5) at a flow rate of 60 µl/min to collect 24 x 60 µl fractions (see Fig. S8A-C). Fractions
16-19 were pooled and 50 µl/well aliquots were loaded into the ELISA plate (Extended Data
Fig. S8). Samples from tga20 mice were diluted 1:2 due to the higher PrPC levels of this mouse
line, and ELISA measurements from these samples were corrected for this dilution factor.
Measurement of PK-resistant PrPSc Protein concentrations in 10% brain homogenates in
PBS were measured by bicinchoninic assay (BCA) and samples were normalized using PBS.
27 µl aliquots of each sample were mixed with 1.5 µl 20% sarcosyl at 37oC for 15 min before
addition of 1.5 µl PK (Roche) to a final concentration of 100 µg/mL and incubation at 37oC
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for 30 min. To facilitate PK digestion samples from tga20 mice only were brought to a final
concentration of 0.375% sodium dodecyl sulphate (SDS) and were digested at 37oC for 30 min
followed by 10 min at 45oC. Protease-digestion was stopped by addition of 1.5 µl 100 mM
phenylmethanesulfonyl fluoride (PMSF) and mixed with 11 µl 8 M Gdn-HCl prior to incuba-
tion for 5 min at 80oC. Samples were then diluted by addition of 362 µl tris buffered saline
containing 0.1% Tween-20 (0.1% TBST) for analysis by an enzyme-linked immunosorbent as-
say (ELISA).
Sample preparation for PrPSc measurements The precipitation of PK-resistant and PK-
sensitive PrPSc was performed as described previously (54) with minor modifications. Samples
were incubated with peptide-coated magnetic beads (M-280; Invitrogen) for 2 h at 37oC with
constant shaking. The beads were washed five times with buffer before denaturation with 0.1 M
NaOH and neutralization with 0.3 M NaH2PO4. The levels of now disaggregated PrP were then
measured by ELISA.
ELISA measurements PrP was measured by a standard ELISA assay using 96-well plates
pre-coated with 2.5 µg/ml POM-2 antibody (55). Bound PrP was detected using a biotinylated
POM-1 antibody (55) (50 ng/ml), followed by streptavidin-HRP (25 ng/ml) and a 1-Step Ultra
TMB-ELISA substrate (Thermo Fisher Scientific) (see Fig. S8D,E). POM-1 was biotinylated
using the EZ-Link™ Sulfo-NHS-LC-Biotinylation Kit (ThermoFisher Scientific). The reaction
was stopped by addition of an equal volume of 2 M sulfuric acid, and the plate was read at
450 nm using an iMark microplate reader (Bio Rad, Hercules CA). RML prion-infected and
uninfected control brain samples were included in every experiment. Samples were run in
triplicate within each ELISA plate and PrP concentrations interpolated from a standard curve
generated using recombinant PrP where possible. Independent ELISAs were performed 3 times.
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Immunoblotting Samples were digested with 20 µg/mL PK, or left undigested, for 30 min
at 37oC, then mixed with an equal volume of 2x LDS loading buffer (Invitrogen) and heated to
95oC prior to electrophoresis through a 10% Bis-Tris gel (Invitrogen). Samples were transferred
to a nitrocellulose membrane by wet blotting. For dot-blotting, 10 µl of undigested samples
were made up to 50 µl with 2x LDS and transferred to a nitrocellulose membrane using the
96-well Bio-Dot apparatus (BioRad) under vacuum. The membrane was then removed for
incubation in the presence of antibodies. Proteins were detected with anti-PrP antibody POM19
followed by an HRP-conjugated anti-mouse IgG antibody (Jackson Immunolabs). Signals were
visualized using a chemiluminescent substrate (Supersignal West DuraR, ThermoScientific) and
an LAS-4000 imager (Fujifilm).
Standard Scrapie Cell Assay (SSCA) for determination of infectivity CAD5 cells were
grown with standard OFBS Medium (Opti-MEM containing 10% FBS, 1% streptomycin and
penicillin, 1%Glutamax; Gibco) in a T150 cell culturing flask. Standard scrapie cell assay was
performed according to published protocols (56), with minor modifications. One day prior to
infection, 10000 CAD5 and CAD5 KO cells lacking PrPC expression were plated with 100 µL
OFBS in 96-well cell culture plates (TPP) and incubated at 37oC with 5% CO2. On the fol-
lowing day, 100 µL of brain homogenate diluted in OFBS mixed with 0.01% brain homogenate
from C57BL/6J-PrnpZH3/ZH3 mice (57) to provide a complex matrix was added to the cells
for the infection. To establish a standard curve for infection, a 1:5 serial dilution of RML6 brain
homogenate (20% w/v in 0.32M sucrose, 109.2 LD50 units per mL) was used with a range from
10−3 to 6.4 ·10−8. For each sample, three different dilutions were performed ranging from 10−3
to 10−5. To control for residual inoculum, CAD5 KO cells were incubated with RML brain
homogenate corresponding to the highest concentration of the standard (0.01%). CAD5 cells
were incubated with (0.01%) non-infectious brain homogenate (10% w/v in 0.32M sucrose) to
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control for efficient PK (Roche) digestion and for computing the background of the assay. Three
days following infection, cells were split 1:8 into new 96 well plates containing fresh OFBS.
After reaching confluence, two additional 1:8 splitting steps were performed, corresponding
to days 7 and 10 post infection. On day 14 post infection, ELISPOT membranes (Millipore)
were activated by adding 50 µL of filtered ethanol/well, washed twice with 160 µL PBS and
nearly 40000 cells per well transferred onto the membrane and dried with a plate thermomixer
(Eppendorf) at 50oC. After drying, plates were stored at 4oC until lysis and digestion. 50 µL
of 0.5 µg/mL PK in lysis buffer (50 mM Tris-HCl pH8, 150 mM NaCl, 0.5% w/v sodium de-
oxycholate, 0.5% w/v Triton-X-100) was added to each well and incubated for 90 minutes at
37oC. Following incubation, vacuum was applied to discard the contents and wells were washed
twice with 160 µL PBS. To stop digestion, 160 µL of 2 mM PMSF (Sigma Aldrich) diluted in
PBS was applied to the membrane and incubated at room temperature for 10 min. Tris guani-
dinium thiocyanate was prepared by diluting 3 M guanidinium thiocyanate in 10 mM Tris HCl
pH8, and added subsequently with a total volume of 160 µL/well and incubated for 10 min.
Supernatant was discarded into 2M NaOH and membrane was washed seven times with each
160 µL PBS and blocked 1 h with 160 µL Superblock (Thermo Scientific) prepared in MilliQ.
Remaining blocking solution was removed under vacuum and 50 µL POM1 antibody (55) was
applied at a concentration of 1:5000 diluted in TBST (10 mM Tris HCl, pH 8, 150 mM NaCl,
0.1% (v/v) Tween 20) containing 1% (w/v) non-fat dry milk for 1 h. Supernatant was discarded
and wells were subsequently washed seven times with TBST under vacuum. 50 µL of anti-
IgG1-AP (Southern Biotechnology Associates) was used with a 1:4500 dilution in TBST-1%
(w/v) non-fat dry milk and incubated for 1 h. Discarding of the supernatant and washing was
performed in the same way as for the POM1 antibody. 50 µL of AP dye (Bio-rad) for the
reaction was applied and incubated for 16 minutes. Membrane was washed twice with water,
dried and stored at -20oC in dark. Quantifications of the membranes were done using ImageJ
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(open source) with optical density, allowing to distinguish between spots (representing cells that
contain PK-resistant PrP) and clear areas.
Measurement of average size of PK resistant PrPSc aggregates in brain homogenates by
Immuno-Diffusional Sizing. Sample preparation: The mice brains were washed with ethanol
(2x, 70%) and sterile PBS (4x). Then they were homogenised in an eight-fold amount of PBS
to prepare a 10% wt. solution with the Ribolyzer tube (speed 6.5, 4x 35s). After the first ho-
mogenisation step the tubes were cooled down on ice and the step was repeated 2 more times.
The homogenates were centrifuged (700 g, 3 min). The supernatant was collected for further
use and the pellet was discarded. Before injection into the microfluidic device, the brain ho-
mogenate (BH) samples were diluted to 1% on tris buffer (50 mM, pH 7.4, 1% wt. BSA).
PK-digestion: tga20-RML infected 10% BH were diluted to 2% in PBS. 10 µl of PK (1000
µg/ml, Cf= 50 µg/ml) was added to 190 µl of 2% BH. The mixture was incubated for 2 hours at
37oC under continuous shaking at 650 rpm. The digestion was stopped by addition of PMSF to
a final concentration of 3 mM and incubation for 15 min with continuous shaking at 750 rpm.
Diffusional Sizing in Microfluidic Devices: The samples were analysed with Western Blot.
For better results, the sample were injected fresh after PK-digestion directly into the microflu-
idic device. The samples were loaded in plastic syringes and injected into a microfluidic device
with an H-filter geometry (58), using positive flow control with Nemesys syringe pumps. For
the non-infected tga20 sample the flow rates for BH and buffer were 95 and 105 µl/h respec-
tively, giving a total flow rate of 200 µl/h with a channel width of 200 µm. For the prion-infected
tga20 the flow rates for BH and buffer were 38 and 42 µl/h respectively, giving a total flow rate
of 80 µl/h with a channel width of 80 µm. Wider channels were required for the non-infected
samples, as the diffusion the small particles detected in those conditions would fully diffuse in
a 80 µm wide channel (see Supplementary Note 4).
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Immunodetection via TR-FRET (PrPC of non-infectious brain homogenate): Concentra-
tions in the diffused and non-diffused fractions were determined using a FRET antibody pair
consisting of Eu-POM19 antibody and APC-POM1 antibody, as detailed previously. (43) Each
aliquot extracted from the outlets (25 µl/well, in triplicates) was mixed with the antibody pair,
Eu-labelled POM1 and APC-labelled POM19 (5 µl each) in a white 384 Opti-well plate (Perkin
Elmer). A standard curve of PrPC from 9.4 nM to 0.05 nM diluted in Tris buffer (50 mM, pH 7,
0.1% BSA) was included for every experiment. After shaking (10 min, RT, 300 rpm), the plate
was incubated overnight at 4oC before measuring it. The FRET signal was measured using the
time-resolved fluorescence mode (emission at 615 nm, second emission at 665 nm), with the
Envision Platereader (Perkin Elmer).
Immunodetection via ELISA (PrPSc after PK-digestion): PK-digested brain homogenate
was injected into a microfluidic device. In order to disassemble the fibrils for detection with
sandwich ELISA, aliquots of the samples extracted from each of the diffused and non-diffused
outlets (162 µl) were mixed with NaOH (21 µl, 0.5 M) and incubated for 10 min at RT under
continuous shaking (700 rpm). 24 µl of neutralising buffer, NaH2PO4 was then added to the
mix and incubated for 10 min at RT under continuous shaking (700 rpm). PrP concentrations in
the diffused and non-diffused fractions were determined using sandwich ELISA. The selected
wells of a transparent 384-well high-binding plate were coated overnight at 4oC with 50 µl
of the capture antibody POM1 (400 ng/ml) in coating buffer (0.1 M Na2CO3/NaHCO3). The
plate was aspirated four times in washing buffer (PBS, 1% Tween) before the addition of 100
µl/well of blocking buffer (5% TopBlock in PBS-T) and incubated for 2h at RT. The plate was
washed 4 times four times in washing buffer before addition of the samples. A standard curve
of recombinant mPrP was included, from serial dilutions 1:2 starting from 0.217 nM to 53 fM.
Recombinant and brain samples were loaded into the plate (50 µl per well) and incubated for
1.5 h at RT. The plate was then washed four times with PBS-T buffer. The detection antibody,
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biotin-labeled POM19 (50 µl, 400 ng/ml) was added in sample buffer (1% Top-Block in PBS-T)
and incubated for 1h at RT. The plate was then washed for times with washing buffer. Avidin-
HRP (50 µl, 2.5 µg/ml) diluted in sample buffer was added and incubated for for 1 h at RT.
The plate was once again washed four times with washing buffer, before adding 50 µl/ well
of stabilised TMB. After 15 min incubation, the reaction was stopped by addition of H2SO4
(0.5 M, 50 µl/well) and the absorbance read at a wavelength of 450 nm using the Envision
Platereader (Perkin Elmer).
Calculation of hydrodynamic radius: To convert the measured ratio of diffused to non-
diffused signal to a hydrodynamic radius, particle-based simulations were performed (44). The
general method was developed and validated in Arosio et al. (59) and we here performed ad-
ditional validation using the same device design and a FRET detection on well-characterised
insulin aggregates (see Extended Data Fig.S7for simulation results and validation).
Fitting of PrPSc concentrations to obtain replication rates. The fits of the fits of the data to
a logistic function, equation (1), was performed by simple least squares assuming homoscedas-
tic noise. The noise in the measurement itself (ELISA) is expected to be largely independent
of the signal strength. The slight increase in noise at later times thus likely reflects the animal-
to-animal variation. To minimise the complexity of the model and the danger of over-fitting
we do not attempt to model this variation explicitly and instead assume homoscedastic noise.
Allowing for heteroscedasticity is unlikely to change the results, given that our conclusions are
robust even with respect to fitting the data with a different model (see Supplementary Note 2).
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